Behavioral effects and in vivo degradation of intraventricularly administered dynorphin-(1-13) and D-Ala2-dynorphin-(1-11) in rats

Add time:09/03/2019    Source:sciencedirect.com

Lateral intraventricular (LV) or cerebral aqueduct (CA) administration of the opioid peptide, dynorphin-(1-13), induced catalepsy and analgesia in rats. Onset was earlier and duration shorter than with morphine or βc-endorphin. The dose required to induce analgesia was reduced at least tenfold when dynorphin-(1-13) was administered into CA rather than LV. An analogue, D-Ala2-dynorphin-(1-11), was more stable than dynorphin-(1-13) in brain, and produced a comparable degree of catalepsy and even more profound analgesia at one-tenth the dose. These effects of dynorphin-(1-13) and D-Ala2-dynorphin-(1-11) were significantly antagonized by naloxone pretreatment. Rats treated with dynorphin-(1-13) or a high dose of D-Ala2-dynorphin-(1-11) exhibited bizarre postures immediately following LV administration, with limb rigidity and “barrel-rolling”. These effects were not blocked by naloxone.

We also recommend Trading Suppliers and Manufacturers of dynorphin A (1-13), Ala(2)-Trp(4)- (cas 104746-05-6). Pls Click Website Link as below: cas 104746-05-6 suppliers

Prev:Systemic administration of dynorphin A(1–13) markedly inhibits different behavioural responses induced by cocaine in the mouse
Next:Dynorphin-A-(1–13) antagonizes morphine analgesia in the brain and potentiates morphine analgesia in the spinal cord)